

Remarks

The instant Action appears to be based on the originally filed claims and not the claims of the preliminary amendment filed along with the Application. As the preliminary amendments are not related to substantive issues, the remarks and amendments herein are based on the claims as in the preliminary amendments as they relate to the comments of the Action.

Claims 1- 37 were pending.

Claims 1-4, 8, 22-27 and 29-37 are cancelled.

Claims 5, 7, 9-21 and 28 are amended.

Claim 6 is as previously amended.

Claims 38-43 are new.

The application now contains claims 5-7, 9-21, 28 and 38-43.

Claims 5 and 7 are amended to incorporate the material from now cancelled claim 1. Claim 5 is further amended to delete reference to formula III. F.23

Claims 9-18, 20, 21 and 28 are amended to replace the word "A" at the beginning of the claim with "The". Claims 9, 11-13, 15-18, 20 and 21 are further amended to be dependent on claim 5. Claim 18 is further amended to replace the word "obtainable" with "obtained". Claim 10 is further amended to be dependent on claim 9.

Claim 19 is further amended to insert the limitation "maleimide" between "electron acceptor" and "compound" in line 2 and to insert the limitation "vinyl ether" between "electron donor" and "compound" in line 3. Support is found in the original claim 19.

Claims 20 and 21 are further amended to insert the limitation "selected from the group consisting of formula I, II, and IV;" into the definition of component d. Claim 21 is also amended to replace the word "a" with "the" immediately prior to the word "composition" in line 2. Support is found in original claims 1, 5 20 and 21. F.23

Claim 28 is further amended to be dependent on claim 7, to delete as redundant the phrase "to the photolatent component (d), " in line 2; to insert the limitation "at least one light stabiliser or/and at least one UV absorber compound and optionally" immediately after the now deleted phrase, and to delete "/and" near the end of the claim. Support is found in original claims 2, 9 and 10.

Support for new claims 38-44 is found in original claims 1, 7, 8, 11, 12, 15, 20 and 21.

No new matter is added.

Objections

Claims 3-18 are objected to for beginning with "A" instead of "The". Applicants submit that the amendments above overcome the objections and kindly ask that they be withdrawn.

Rejections

Claims 1-4 and 19-21 are rejected under 35 USC 103(a) as being obvious over Borden et.al., US 3,943,103.

Claims 1-4 are rejected under 35 USC 103(a) as being obvious over Carder et.al., US 3,939,126.

Applicants respectfully traverse the rejections.

Claims 1-4 are cancelled. Claim 19 is amended to limit the electron acceptor compound to a maleimide and the electron donor compound to a vinyl ether. This mixture of donor and acceptor are not found in Border. Claims 20 and 21 are amended to incorporate the limitations of claim 5. As Borden and Carder are silent regarding compounds of Formula I, II and IV Applicants respectfully submit that the rejections are overcome and kindly ask that they be withdrawn.

Claims 5 and 6 are rejected under 35 USC 103(a) as being obvious over Borden US 3,943,103 above in view of McGinness, US 3,847,771 which discloses certain synergistic sensitizers that appear to overlap with those of the instant invention.

Applicants respectfully traverse the rejections.

Compounds of instant formula III, which appear to overlap with the benzophenones of McGinness are deleted from the instant claims.

Applicants respectfully note that the compounds of instant formula I all have non-hydrogen substituents at R 1, R2 and R3, i.e., adjacent to the carbonyl. The benzoins etc of McGinness are not so substituted. Applicants further respectfully note that the compounds of formula II contain a substituted phosphorous oxide group adjacent to the carbonyl and the compounds of formula IV contain a carboxylic ester adjacent to the carbonyl. Applicants respectfully aver that these compounds are outside those disclosed in McGinness.

In light of the instant amendments Applicants respectfully submit that the rejections of claims 5 and 6 under 35 USC 103(a) over Borden US 3,943,103 in view of McGinness, US 3,847,771 are overcome and kindly ask that the rejections be withdrawn.

Claim 7 is rejected under 35 USC 103(a) as being obvious over Borden US 3,943,103 above in view of McGinness, US 3,847,771 and Toba JP 10158039.

Applicants respectfully traverse the rejections.

The Action states that Toba discloses the use of diphenyl(9-anthrylmethyl)sulfonium borate salt which overlaps with the instant invention, citing instant formula V. Applicants respectfully note that instant formula V is a diphenyl iodonium and assume that the Examiner intended to cite the sulfonium salts of instant formula VI. Applicants respectfully point out that the instant sulfonium salts are either substituted by three phenyl rings which may be substituted by S-Phenyl or triphenyl sulfonium. There is thus no overlap between the compounds of component d in instant claim 8 and Toba. The combined art therefore does not meet the limitations of claim 8.

In light of the discussion above Applicants respectfully submit that the rejections of claim 7 under 35 USC 103(a) over Borden US 3,943,103 in view of McGinness, US 3,847,771 and Toba JP 10158039 are overcome and kindly ask that the rejections be withdrawn.

Claims 8-18 are rejected under 35 USC 103(a) as being obvious over Borden US 3,943,103 above in view of McGinness, US 3,847,771 and Klinkenberg, US 2002/0076504.

Applicants respectfully traverse the rejections.

Claim 8 is cancelled.


Regarding claims 9-18, Applicants respectfully note that they now relate specifically only to the method of instantly amended claim 5 which claim Applicants believe is now allowable as described above.

Applicants further note that claims 28 and 38-43 now relate specifically only to the method of instantly amended claim 7 which claim Applicants believe is now allowable as described above.

In light of the amendments and discussion above Applicants respectfully submit that the rejections of claims 8-18 under 35 USC 103(a) over Borden US 3,943,103 in view of McGinness, US 3,847,771 and Klinkenberg, US 2002/0076504 are overcome and kindly ask that the rejections be withdrawn.

Applicants therefore respectfully submit that all objections and rejections are addressed and are overcome and kindly ask that they be withdrawn and claims 5-7, 9-21, 28 and 38-43 be found allowable. In the event that minor amendments will further prosecution, Applicants request that the examiner contact the undersigned representative.

Respectfully submitted,



Joseph C. Suhadolnik
Agent for Applicants
Reg. No. 56,880
filed under 37 CFR 1.34(a)

Ciba Specialty Chemicals Corporation
Patent Department
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
Tel. (914) 785-2973
Fax (914) 785-7102